JP2021516996A5 - - Google Patents

Info

Publication number
JP2021516996A5
JP2021516996A5 JP2020571337A JP2020571337A JP2021516996A5 JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5 JP 2020571337 A JP2020571337 A JP 2020571337A JP 2020571337 A JP2020571337 A JP 2020571337A JP 2021516996 A5 JP2021516996 A5 JP 2021516996A5
Authority
JP
Japan
Prior art keywords
human
polypeptide
cells
amino acid
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516996A (ja
JP7846963B2 (ja
Filing date
Publication date
Priority claimed from US15/916,689 external-priority patent/US10869887B2/en
Application filed filed Critical
Publication of JP2021516996A publication Critical patent/JP2021516996A/ja
Publication of JP2021516996A5 publication Critical patent/JP2021516996A5/ja
Priority to JP2023204147A priority Critical patent/JP2024037778A/ja
Application granted granted Critical
Publication of JP7846963B2 publication Critical patent/JP7846963B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571337A 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン／受容体対 Active JP7846963B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023204147A JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン／受容体対

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US15/916,689 US10869887B2 (en) 2015-09-11 2018-03-09 Biologically relevant orthogonal cytokine/receptor pairs
US15/916,689 2018-03-09
PCT/US2019/021451 WO2019173773A1 (en) 2015-09-11 2019-03-08 Biologically relevant orthogonal cytokine/receptor pairs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023204147A Division JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン／受容体対

Publications (3)

Publication Number Publication Date
JP2021516996A JP2021516996A (ja) 2021-07-15
JP2021516996A5 true JP2021516996A5 (https=) 2022-03-16
JP7846963B2 JP7846963B2 (ja) 2026-04-16

Family

ID=58240003

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018513275A Active JP7299021B2 (ja) 2015-09-11 2016-09-07 生体関連の直交性サイトカイン／受容体ペア
JP2020571337A Active JP7846963B2 (ja) 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン／受容体対
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン／受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン／受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン／受容体ペア

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018513275A Active JP7299021B2 (ja) 2015-09-11 2016-09-07 生体関連の直交性サイトカイン／受容体ペア

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン／受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン／受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン／受容体ペア

Country Status (18)

Country Link
US (7) US10869887B2 (https=)
EP (2) EP3347056A4 (https=)
JP (5) JP7299021B2 (https=)
KR (3) KR102739782B1 (https=)
CN (4) CN117659160A (https=)
AR (1) AR114687A1 (https=)
AU (3) AU2016318621A1 (https=)
BR (1) BR112020018293A2 (https=)
CA (2) CA2998393A1 (https=)
HK (1) HK1258138A1 (https=)
IL (2) IL313413A (https=)
MX (1) MX2020009330A (https=)
PH (1) PH12020551417A1 (https=)
RU (1) RU2020133171A (https=)
SG (1) SG11202008780SA (https=)
TW (1) TW202017576A (https=)
WO (2) WO2017044464A1 (https=)
ZA (1) ZA202006168B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117659160A (zh) 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3123392A1 (en) * 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020187848A1 (en) * 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
PH12022550326A1 (en) * 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
EP4041760A4 (en) * 2019-10-08 2023-10-11 Zymeworks BC Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
CN121517534A (zh) 2019-12-13 2026-02-13 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
AU2021208559A1 (en) * 2020-01-14 2022-07-07 Synthekine, Inc. CD122 with altered ICD STAT signaling
KR20220141299A (ko) * 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3169095A1 (en) * 2020-03-05 2021-09-10 Kenan Christopher GARCIA Designed il-2 variants
US20230159892A1 (en) * 2020-04-06 2023-05-25 Synthekine, Inc. Engineered immune cells
CA3179414A1 (en) * 2020-04-06 2021-10-14 Synthekine, Inc. Human immune cells genomically modified to express orthogonal receptors
WO2022050401A2 (en) * 2020-09-01 2022-03-10 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
JP2023549293A (ja) * 2020-10-26 2023-11-22 ネプチューン バイオサイエンシズ エルエルシー 直交ｉｌ－２１受容体／サイトカイン系
WO2022192346A1 (en) * 2021-03-09 2022-09-15 The Trustees Of The University Of Pennsylvania Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2
WO2022212918A1 (en) * 2021-04-02 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific molecules and related compositions and methods
AU2022254143A1 (en) * 2021-04-07 2023-11-23 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20250288666A1 (en) * 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
AU2022348588A1 (en) 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
EP4504247A1 (en) * 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
EP4724504A1 (en) * 2023-06-07 2026-04-15 FBD Biologics Limited Engineered il-7 variants and methods of use thereof
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US20060199250A1 (en) * 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
CN117659160A (zh) * 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
JP2021516996A5 (https=)
CN110818802B (zh) 一种嵌合t细胞受体star及其应用
RU2020133171A (ru) Биологически значимые ортогональные пары цитокинов/рецепторов
US10725044B2 (en) T cell receptors and immune therapy using the same
CN108603200B (zh) 优化的慢病毒转移载体及其用途
JP6422134B2 (ja) キメラ抗原受容体
CN105377886B (zh) 识别mage-a1的高亲和力结合分子
US12497453B2 (en) ROR1 specific chimeric antigen receptors and their therapeutic applications
CN107074929B (zh) 嵌合自身抗体受体t细胞的组合物和方法
BR112020024246A2 (pt) pelo menos um polinucleotídeo recombinante, célula recombinante, receptor de antígeno quimérico, polinucleotídeo que codifica o receptor de antígeno quimérico, vetor, vírus, composição farmacêutica, e, método para tratar câncer
JP2017530724A (ja) 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用
US20060263334A1 (en) Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
AU2019370618C1 (en) Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof
JP7606510B2 (ja) Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物
CN107108752A (zh) 基于t细胞的免疫治疗药
CN115315270A (zh) 工程化免疫细胞
AU2019406447A1 (en) CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies
JP7429462B2 (ja) Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体
CN116194574A (zh) 嵌合抗原受体细胞
KR102961312B1 (ko) CAR를 발현하는 면역세포와 항원제시세포를 맺어주는 이종(allogeneic) 폴리펩타이드 및 이의 용도
HK40049020A (en) Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
CN115725504A (zh) 工程化免疫细胞及其用途
CN118574843A (zh) 以可检测的亲和力结合特异性肽的抗原识别构建体和对kras具有抗原特异性的t细胞受体以及相应的核酸序列、载体、宿主细胞、药物组合物和试剂盒
Powell Jr et al. Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy
BR112016020518B1 (pt) Receptor antigênico quimérico